Hatch-Waxman “Safe Harbor” Ruling Threatens Compound Patents, Momenta Says
Executive Summary
Enoxaparin marketing partners Momenta and Sandoz seek rehearing en banc of an appellate panel’s decision that broadly interpreted the scope of the so-called “Bolar Amendment.” Amphastar and Watson, whom the panel said were protected from patent infringement claims, oppose the request.